Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2018 | 1 |
2019 | 3 |
2020 | 1 |
2021 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
Lancet. 2019.
PMID: 31590988
Clinical Trial.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.
Mok TSK, et al.
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
Lancet. 2019.
PMID: 30955977
Clinical Trial.
Item in Clipboard
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators.
Goldman JW, et al.
Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
Lancet Oncol. 2021.
PMID: 33285097
Clinical Trial.
Item in Clipboard
The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
Pósfai B, Kuthi L, Varga L, Laczó I, Révész J, Kránicz R, Maráz A.
Pósfai B, et al. Among authors: laczo i.
Anticancer Res. 2018 Jun;38(6):3243-3254. doi: 10.21873/anticanres.12589.
Anticancer Res. 2018.
PMID: 29848671
Free article.
Review.
Item in Clipboard
[Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
Nagykálnai T, Landherr L, Laczó I, Pikó B.
Nagykálnai T, et al. Among authors: laczo i.
Magy Onkol. 2015 Sep;59(3):251-7. Epub 2015 Mar 1.
Magy Onkol. 2015.
PMID: 26339914
Free article.
Review.
Hungarian.
Item in Clipboard
[Rare, but existing clinical entity - the neuroendocrine cancer of the bladder].
Pikó B, Kis A, Laczó I, Mészáros T, Bassam A.
Pikó B, et al. Among authors: laczo i.
Magy Onkol. 2021 Dec 7;65(4):355-358. Epub 2021 Nov 15.
Magy Onkol. 2021.
PMID: 34874367
Free article.
Hungarian.
Item in Clipboard
ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer.
Küronya Z, Sükösd F, Varga L, Bíró K, Gyergyay F, Géczi L, Nagyiványi K, Jorgo K, Szarvas T, Kovács Á, Laczó I, Varga Z, Pósfai B, Pepó J, Maráz A.
Küronya Z, et al. Among authors: laczo i.
Urol Oncol. 2019 Apr;37(4):289.e1-289.e9. doi: 10.1016/j.urolonc.2018.12.007. Epub 2019 Jan 21.
Urol Oncol. 2019.
PMID: 30679082
Item in Clipboard
Cite
Cite